Last Updated: September 28 2022

Serrapeptase is an enzyme derived from silkworms. It has anti-inflammatory effects and can help prevent blood clots, but these effects are somewhat unreliable.

Serrapeptase is most often used for


Serrapeptase is a proteolytic (protein destroying) enzyme from bacteria native to the digestive system of silkworms. It is the enzyme responsible for dissolving a silkworm’s cocoon.

Traditionally, serrapeptase has been used for its anti-inflammatory properties. Today, it is marketed as a joint health supplement.

Unfortunately, many studies on serrapeptase were poorly structured, with inadequate control groups. The most recent data suggests that serrapeptase is not a very effective supplement, as far as joint health and inflammation is concerned.

Though serrapeptase has been detected in plasma after supplementation, the standard oral dose for serrapeptase is low, which means very little is absorbed through the intestines. This may be one of the reasons serrapeptase is unreliable and not very effective.

Serrapeptase has been found to have the ability to liquefy mucus and reduce bacterial biofilms (reducing bacteria’s ability to stick to surfaces and each other). This means serrapeptase may be able to reduce phlegm buildup, nasal discharge, lung symptoms of cystic fibrosis and help other compounds fight bacteria. Additional research is needed to confirm these effects.

What else is Serrapeptase known as?
Note that Serrapeptase is also known as:
  • Serratiopeptidase
  • Serratia E-15
  • serralysin
  • serratiaprotease
  • Silk worm enzymes
Dosage information

The standard dose for serrapeptase is 10-60mg.

Serrapeptase should be supplemented on an empty stomach, which is 30 minutes before a meal or two hours after a meal, three times a day. Most studies use 10mg of serrapeptase taken every eight hours.

More human evidence is needed to determine the optimal dose of serrapeptase. 10mg of serrapeptase is equal to approximately 20,000 enzymatic units.

Join our supplement information course

Examine Database: Serrapeptase
What works and what doesn't?

Unlock the full potential of Examine

Get started

Don't miss out on the latest research

1.^Bhagat S, Agarwal M, Roy VSerratiopeptidase: a systematic review of the existing evidenceInt J Surg.(2013)
2.^Badhe RV, Nanda RK, Kulkarni MB, Bhujbal MN, Patil PS, Badhe SRMedia optimization studies for Serratiopeptidase production from Serratia marcescens ATCC 13880Hindustan Antibiot Bull.(2009)
6.^Bromke BJ, Hammel JMRegulation of extracellular protease formation by Serratia marcescensCan J Microbiol.(1979 Jan)
7.^Matsumoto K, Maeda H, Takata K, Kamata R, Okamura RPurification and characterization of four proteases from a clinical isolate of Serratia marcescens kums 3958J Bacteriol.(1984 Jan)
8.^Selan L, Berlutti F, Passariello C, Comodi-Ballanti MR, Thaller MCProteolytic enzymes: a new treatment strategy for prosthetic infectionsAntimicrob Agents Chemother.(1993 Dec)
11.^Umashankar MS, Sachdeva RK, Gulati MAquasomes: a promising carrier for peptides and protein deliveryNanomedicine.(2010 Jun)
13.^Moriya N, Nakata M, Nakamura M, Takaoka M, Iwasa S, Kato K, Kakinuma AIntestinal absorption of serrapeptase (TSP) in ratsBiotechnol Appl Biochem.(1994 Aug)
14.^Woodley JFEnzymatic barriers for GI peptide and protein deliveryCrit Rev Ther Drug Carrier Syst.(1994)
17.^Obata K, Sugano K, Saitoh R, Higashida A, Nabuchi Y, Machida M, Aso YPrediction of oral drug absorption in humans by theoretical passive absorption modelInt J Pharm.(2005 Apr 11)
20.^Kakinuma A, Moriya N, Kawahara K, Sugino HRepression of fibrinolysis in scalded rats by administration of Serratia proteaseBiochem Pharmacol.(1982 Sep 15)
24.^Jadav SP, Patel NH, Shah TG, Gajera MV, Trivedi HR, Shah BKComparison of anti-inflammatory activity of serratiopeptidase and diclofenac in albino ratsJ Pharmacol Pharmacother.(2010 Jul)
25.^Tachibana M, Mizukoshi O, Harada Y, Kawamoto K, Nakai YA multi-centre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swellingPharmatherapeutica.(1984)
28.^Panagariya A, Sharma AKA preliminary trial of serratiopeptidase in patients with carpal tunnel syndromeJ Assoc Physicians India.(1999 Dec)
32.^Christner M, Franke GC, Schommer NN, Wendt U, Wegert K, Pehle P, Kroll G, Schulze C, Buck F, Mack D, Aepfelbacher M, Rohde HThe giant extracellular matrix-binding protein of Staphylococcus epidermidis mediates biofilm accumulation and attachment to fibronectinMol Microbiol.(2010 Jan)
34.^Artini M, Papa R, Scoarughi GL, Galano E, Barbato G, Pucci P, Selan LComparison of the action of different proteases on virulence properties related to the staphylococcal surfaceJ Appl Microbiol.(2013 Jan)
35.^Artini M, Scoarughi GL, Papa R, Cellini A, Carpentieri A, Pucci P, Amoresano A, Gazzola S, Cocconcelli PS, Selan LA new anti-infective strategy to reduce adhesion-mediated virulence in Staphylococcus aureus affecting surface proteinsInt J Immunopathol Pharmacol.(2011 Jul-Sep)
36.^Longhi C, Scoarughi GL, Poggiali F, Cellini A, Carpentieri A, Seganti L, Pucci P, Amoresano A, Cocconcelli PS, Artini M, Costerton JW, Selan LProtease treatment affects both invasion ability and biofilm formation in Listeria monocytogenesMicrob Pathog.(2008 Jul)
38.^Costerton JW, Cheng KJ, Geesey GG, Ladd TI, Nickel JC, Dasgupta M, Marrie TJBacterial biofilms in nature and diseaseAnnu Rev Microbiol.(1987)
39.^Lee HS, Majima Y, Sakakura Y, Kim BWA technique for quantitative cytology of nasal secretionsEur Arch Otorhinolaryngol.(1991)
40.^Nakamura S, Hashimoto Y, Mikami M, Yamanaka E, Soma T, Hino M, Azuma A, Kudoh SEffect of the proteolytic enzyme serrapeptase in patients with chronic airway diseaseRespirology.(2003 Sep)
41.^Majima Y, Hirata K, Takeuchi K, Hattori M, Sakakura YEffects of orally administered drugs on dynamic viscoelasticity of human nasal mucusAm Rev Respir Dis.(1990 Jan)
42.^Majima Y, Inagaki M, Hirata K, Takeuchi K, Morishita A, Sakakura YThe effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucusArch Otorhinolaryngol.(1988)
43.^Shimura S, Okubo T, Maeda S, Aoki T, Tomioka M, Shindo Y, Takishima T, Umeya KEffect of expectorants on relaxation behavior of sputum viscoelasticity in vivoBiorheology.(1983)
44.^Mecikoglu M, Saygi B, Yildirim Y, Karadag-Saygi E, Ramadan SS, Esemenli TThe effect of proteolytic enzyme serratiopeptidase in the treatment of experimental implant-related infectionJ Bone Joint Surg Am.(2006 Jun)
47.^Viswanatha Swamy AH, Patil PAEffect of some clinically used proteolytic enzymes on inflammation in ratsIndian J Pharm Sci.(2008 Jan)
48.^Shimizu H, Ueda M, Takai T, Bito T, Ichihashi M, Muramatsu T, Shirai TA case of serratiopeptidase-induced subepidermal bullous dermatosisBr J Dermatol.(1999 Dec)